Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 38,074 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 38,074 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $15.09, for a total value of $574,536.66. Following the sale, the insider owned 321,967 shares in the company, valued at approximately $4,858,482.03. The trade was a 10.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Francis Lo also recently made the following trade(s):

• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.73, for a total transaction of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.08, for a total transaction of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $14.95 on Tuesday. The company has a 50 day moving average price of $16.76 and a 200 day moving average price of $15.87. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -37.37 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.23) EPS. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth about $28,000. Sound Income Strategies LLC bought a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at approximately $30,000. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. boosted its position in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the fourth quarter worth approximately $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.